ESR1 and neoplasm: Conversely, liquiritigenin is a highly selective ERβ agonist which does not stimulate ERα positive tumor formation [61] or ERα homodimerization [58] suggesting that it may serve as a suppressor of proliferation in ERβ expressing cells.